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matrix and have proproliferative and
proangiogenic activities. Consistently,
the upregulation of IL-13 has been linked
to progression of liver fibrosis (Reiman
et al., 2006). In this context, and following
the two reports highlighted herein, it
becomes a high priority to evaluate how
modifying Kupffer cell phenotype, via
PPARd/b agonists (or antagonists) or
other means, would affect the evolution
and prognosis of nonalcoholic hepatic
steatosis.
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Niemann-Pick C1-like 1 (NPC1L1) is a target for ezetimibe, a drug that blocks intestinal cholesterol absorp-
tion. A new study by Ge et al. (2008) in this issue of Cell Metabolism shows that non-lipoprotein-bound
cholesterol induces endocytosis of NPC1L1 and that ezetimibe blocks the internalization of the NPC1L1/cho-
lesterol complex. The in vivo significance of these findings is discussed.Cholesterol is essential for the growth and
maintenance of all mammalian cells. An
elevated level of low-density lipoprotein
(LDL) cholesterol, however, is a major
risk factor for atherosclerotic cardiovas-
cular diseases. Although the statin drugs
have significantly reduced the mortality
of patients suffering from coronary heart
disease (CHD), the risk of death among
individuals with CHD remains high. There-
fore, it is desirable to develop other drugs
that complement the action of statins.
Cholesterol in the body is derived from
two different sources, endogenous syn-
thesis and diet. Statins inhibit the enzyme
HMG-CoA reductase, thereby reducing
endogenous sterol synthesis, and cause
a compensatory increase in LDL receptor
expression. LDL receptor expression inthe liver is a major determinant of serum
LDL cholesterol levels. Statins cannot
block cholesterol uptake from dietary
sources, whereas ezetimibe (trade names
Zetia, Ezetrol, and Ezemibe), a recently
approved drug, does so efficiently.
When coadministered with a statin, ezeti-
mibe reduces patients’ serum LDL cho-
lesterol levels more than statin alone.
Ezetimibe is known to block Niemann-
Pick C1-like 1 (NPC1L1), although the
mechanism of this action is unclear. A new
study by Ge, Wang, and colleagues (Ge
et al., 2008) in this issueofCellMetabolism
shows that NPC1L1 mediates cholesterol
uptake via vesicular endocytosis and that
ezetimibe inhibits cholesterol absorption
by blocking the internalization of NPC1L1
protein.Cell MetaboEzetimibe was originally identified as
a weak inhibitor of the enzyme acyl-coen-
zymeA:cholesterol acyltransferase (ACAT).
There are two ACAT genes, ACAT1 and
ACAT2, which encode two enzymes with
similar biochemical properties. In various
cell types, ACAT1 converts excess cellu-
lar cholesterol to cholesteryl esters (CEs)
for storage (Chang et al., 2006), while in
intestinal enterocytes, ACAT2 produces
CEs that become part of the lipid cargo
present in the lipoproteins known as chy-
lomicrons (Buhman et al., 2000). Once as-
sembled, chylomicrons are secreted into
the bloodstream for delivery of lipid cargo
to various tissues. Further investigation
has demonstrated that ezetimibe does
not target ACAT. In animals, ezetimibe
efficiently blocks intestinal cholesterollism 7, June 2008 ª2008 Elsevier Inc. 469
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Previewsabsorption at drug concentrations much
lower than that needed to inhibit ACAT
activity. Themolecular target of ezetimibe,
however, remained elusive for several
years. The target was expected to reside
at the surface of the intestinal epithelium
based on the observation that in animal
studies, the membrane-impermeable
metabolite of ezetimibe (ezetimibe glucur-
onidate) was more efficient in blocking
cholesterol absorption than ezetimibe
itself.
The NPC1L1 protein was identified
based on its high sequence homology
with the protein NPC1 (Davies et al.,
2000), which was named for the rare, fatal
genetic disease Niemann-Pick type C.
This disease can be caused by mutations
in two different genes, NPC1 and NPC2470 Cell Metabolism 7, June 2008 ª2008 Els(Patterson et al., 2001). NPC1 is a multi-
spanmembrane protein located in the en-
dosomes of various cell types. It contains
a motif called the sterol-sensing domain,
present only in a few membrane proteins
involved in cholesterol-related cellular
events. NPC1 binds sterols, and muta-
tions within NPC1 cause a defect in cho-
lesterol egress from the endosomal com-
partment (Chang et al., 2006). NPC1L1 is
also a multispan membrane protein and
contains a sterol-sensing domain. Unlike
NPC1, NPC1L1 is expressed mainly in
the small intestine. In humans, but not in
mice, NPC1L1 is also expressed in the
canalicular membrane of hepatocytes,
the site of bile acid secretion. These and
other features led Garcia-Calvo and
colleagues (2005) to demonstrate thatevier Inc.NPC1L1 binds ezetimibe specifically and
that NPC1L1 is indeed the main target
for ezetimibe.
In model systems, NPC1L1 resides in
several cellular compartments. Earlier,
Yu and colleagues (2006) showed that
cellular cholesterol depletion causes
NPC1L1 to relocate from the cell interior
to the plasma membrane (PM). In this
issue of Cell Metabolism, Ge et al. (2008)
show that in cells ectopically expressing
NPC1L1, adding exogenous cholesterol
causes rapid internalization of NPC1L1
from the PM to the cell interior. Other ste-
rols, oxysterols, or bile acids added exter-
nally do not produce the same effect.
Upon adding external cholesterol,
NPC1L1 appears transiently in clathrin-
coated vesicles. Surprisingly, the rapidFigure 1. Cholesterol Absorption at the Intestinal Epithelium
Cholesterol by itself is insoluble in water. The digestion process that occurs in the intestinal lumen solubilizes dietary cholesterol in the form of intestinal mixed
micelles, which consist of bile salts, unesterified fatty acids, unesterified cholesterol (CHOL), partially degraded complex lipids, and other lipophilic substances
including fat-soluble vitamins. Niemann-Pick C1-like 1 (NPC1L1) is located in both the apical membrane and certain internal membranes. The uptake of CHOL
into intestinal enterocytes involves endocytosis of the NPC1L1/cholesterol complex at the apical membrane and is largely blocked by the drug ezetimibe. The
ATP-binding cassette (ABC) protein complex ABCG5/G8, also located at the apical membrane, facilitates the exit of CHOL back to the intestinal lumen to guard
against unnecessary CHOL buildup (Berge et al., 2000). The fatty acid translocase CD36 and the scavenger receptor BI (SRBI) may also participate in intestinal
cholesterol uptake. Inside the cell, a portion of CHOL is esterified to cholesteryl esters (CE) by the enzyme ACAT2. CHOL, CE, TAG (triacylglycerol, derived from
dietary fatty acids), and a large protein called apoB48 assemble together to form a lipoprotein complex called the chylomicron, which is secreted from the in-
tercellular space into the lymph and enters the veins for systemic circulation. A portion of CHOL may also efflux to the high-density lipoprotein (HDL) in blood
via a different ABC protein, ABCA1, located at the basolateral membrane. The linked black arrows indicate the involvement of several cholesterol trafficking
routes; their molecular nature remains largely unknown.
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Previewsinternalization of NPC1L1 is accompanied
by the rapid appearance and accumula-
tion of cholesterol at the cell interior. Since
the experiments were performed in media
lacking any lipoproteins, these results
imply that NPC1L1 acts as a receptor for
non-lipoprotein-bound cholesterol and
brings it to the cell interior through recep-
tor-mediated endocytosis. Contrary to
prior expectations, NPC1L1 does not
function as a cholesterol transporter,
which would act to facilitate the move-
ment of external substances across the
phospholipid bilayer of the biological
membrane. In addition to clarifying the ac-
tion of NPC1L1, the authors demonstrate
that ezetimibe blocks the endocytosis of
NPC1L1 induced by cholesterol loading,
although it does not block the exocytosis
of NPC1L1 induced by cholesterol deple-
tion. This work advances our understand-
ing of the role of NPC1L1 in cellular cho-
lesterol delivery and helps explain the
action of ezetimibe as a cholesterol ab-
sorption inhibitor.
Ge et al. (2008) used several model cell
systems for their study. Based on their
work, we present a model that describes
the role of NPC1L1 and the action of eze-
timibeat the intestinal epithelium(Figure1).
This model suggests that dietary choles-
terol induces endocytosis of NPC1L1 at
the cell surface and that ezetimibe blocks
the internalization of the NPC1L1/cho-
lesterol complex. The NPC1L1-mediated
cholesterol uptake process is somewhat
similar to the process by which the LDL
receptors bring cholesterol to the cell
interior (Brown and Goldstein, 1986), butsome differences are worth noting. Unlike
the LDL receptor, which takes up choles-
teryl esters, NPC1L1 brings in unesterified
cholesterol. Also, the endocytosis of
NPC1L1 is induced only when the ligand
(unesterified cholesterol) is present in
abundance. By contrast, the LDL receptor
brings in cholesteryl esters bound to the
LDL, and the endocytosis of the LDL re-
ceptor is continuous with or without the
ligand (LDL). In addition, unlike the LDL
receptor, a large NPC1L1 pool exists at
the cell interior. Figure 1 also describes
various other related processes at the
intestinal epithelium.
Several issues remain to be resolved by
future studies: namely, whether NPC1L1
binds to cholesterol present in the intesti-
nal mixed micelles or cholesterol that ac-
cumulates at the apical membrane, how
NPC1L1 releases the bound cholesterol,
and what happens to cholesterol released
by NPC1L1. Recent studies suggest that
the fatty acid translocase CD36 and the
scavenger receptor BI (SRBI) may also
participate in intestinal cholesterol uptake
and that ezetimibe may have additional
targets (Hui et al., 2008; Nauli et al.,
2006). It will be important to clarify the
potential functional relationship among
NPC1L1, CD36, SRBI, and other ezeti-
mibe targets. Elucidating the roles
of these other molecules and the various
cholesterol trafficking processes high-
lighted in Figure 1 will further improve
our understanding of intestinal cholesterol
absorption, which may facilitate the
search for other inhibitors of dietary
cholesterol absorption.Cell MetaboREFERENCES
Berge, K.E., Tian, H., Graf, G.A., Yu, L., Grishin,
N.V., Schutltz, J., Kwiterovitch, P., Shan, B.,
Barnes, R., and Hobbs, H.H. (2000). Science 290,
1771–1775.
Brown, M.S., and Goldstein, J.L. (1986). Science
232, 34–47.
Buhman, K.K., Accad, M., Novak, S., Choi, R.S.,
Wong, J.S., Hamilton, R.L., Turley, S., and Farese,
R.V., Jr. (2000). Nat. Med. 6, 1341–1347.
Chang, T.Y., Chang, C.C., Ohgami, N., and
Yamauchi, Y. (2006). Annu. Rev. Cell Dev. Biol.
22, 129–157.
Davies, J.P., Levy, B., and Ioannou, Y.A. (2000).
Genomics 65, 137–145.
Garcia-Calvo, M., Lisnock, J., Bull, H.G., Hawes,
B.E., Burnett, D.A., Braun, M.P., Crona, J.H., Da-
vis, H.R., Jr., Dean, D.C., Detmers, P.A., et al.
(2005). Proc. Natl. Acad. Sci. USA 102, 8132–8137.
Ge, L., Wang, J., Qi, W., Miao, H.-H., Cao, J., Qu,
Y.-X., Li, B.-L., and Song, B.-L. (2008). Cell Metab.
7, this issue, 508–519.
Hui, D.Y., Labonte, E.D., and Howles, P.N. (2008).
Am. J. Physiol. Gastrointest. Liver Physiol. 294,
G839–G843.
Nauli, A.M., Nassir, F., Zheng, S., Yang, Q., Lo,
C.M., Vonlehmden, S.B., Lee, D., Jandacek, R.J.,
Abumrad, N.A., and Tso, P. (2006). Gastroenterol-
ogy 131, 1197–1207.
Patterson, M.C., Vanier, M.T., Suzuki, K., Morris,
J.A., Carstea, E., Neufeld, E.B., Blanchette-
Mackie, J.E., and Pentchev, P.G. (2001).
Niemann-Pick disease type C: A lipid trafficking
disorder. In The Metabolic and Molecular Bases
of Inherited Disease, C.R. Scriver, A.L. Beaudet,
W.S. Sly, and D. Valle, eds. (New York: McGraw-
Hill), pp. 3611–3633.
Yu, L., Bharadwaj, S., Brown, J.M., Ma, Y., Du, W.,
Davis, M.A., Michaely, P., Liu, P., Willingham,
M.C., and Rudel, L.L. (2006). J. Biol. Chem. 281,
6616–6624.lism 7, June 2008 ª2008 Elsevier Inc. 471
